BIRC5 and cancer: Consistent with our early data and our rationale, bortezomib-mediated inhibition of cell growth is significantly better in cancer cell lines with wild type p53 in comparison to those cell lines with a p53 null or p53 mutant status (Fig. 7), which is consistent with the relative expression level of survivin in these cells (Fig. 3A and 3B).